Cumberland Pharmaceuticals Inc. ((CPIX)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
In a recent update, Cumberland Pharmaceuticals Inc. announced progress in their phase 2 clinical study titled A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients With Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension (SSc-PAH). The study aims to evaluate the safety and effectiveness of ifetroban, a drug intended to treat these conditions, which are characterized by significant morbidity.
The study tests oral ifetroban, a drug designed to potentially reduce disease effects and prevent progression in patients with early-stage disease, while reversing established disease in those with longer disease duration. Participants receive either ifetroban or a placebo daily for a year.
This interventional study employs a randomized, parallel assignment model with quadruple masking, ensuring that participants, care providers, investigators, and outcomes assessors are unaware of the treatment allocations. The primary goal is treatment-focused.
Key dates include the study’s start in January 2017, with the latest update submitted in July 2025. These dates are crucial for tracking progress and anticipating results.
The study’s progress could influence Cumberland Pharmaceuticals’ stock performance and investor sentiment, especially if the results demonstrate significant efficacy. This could also impact the competitive landscape in the treatment of SSc and SSc-PAH.
The study remains active but is not recruiting, with further details available on the ClinicalTrials portal.